- The Wall Street Journal•1 hour ago
AstraZeneca posted a loss in the second quarter as it furiously invested in its next-generation drugs while battling falling sales of its aging blockbuster Crestor, and took a restructuring charge relating ...
- Associated Press•2 hours ago
LONDON (AP) — Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 percent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States.
|Bid||4,760.00 x 6100|
|Ask||4,760.50 x 13000|
|52wk Range||3,680.00 - 4,771.00|
|Day's Range||4,637.05 - 4,771.00|
|Avg Vol (3m)||2,612,042|
As of 4:42 AM EDT. LSE Delayed Price. Market open.